shocked the world with the first human to human heart transplant. ... Questions Remain on. Routine ..... to answer the questions of clinical efficacy and safety.
(hallux rigidus). An orthotic with a rigid, finger-like projection under the big toe prevents painful movement of the toe. Also helpful is a traditional rocker bottom ...
nomas â whose cells typically look and act .... Health Letter, Subscription Services, P.O. Box 9302,. Big Sandy, TX ... Barium enema (colon X-ray). â This test ... Like a barium enema, it involves radiation ..... wash your hands with soap and.
Nov 10, 2011 - Current Trends in the Practice of Medicine. Vol. 27, No. 5, 2011. INSIDE THIS ISSUE. 2Enhanced Recovery. Pathway: Rethinking. Pre- and Postoperative. Surgical Care for. Colorectal Patients ..... titioners, internists, general practitio
energy you burn. Overeating and lack of physical activity are the main reasons why people pack on excess pounds. However, aging also can contribute to weight gain as well as to an increase in body fat. That's because as you age, you gradually lose mu
SARS Revisited: The Challenge of Controlling Emerging Infectious Diseases at the Local ..... Addressing New Emerging Infectious Disease Threats and.
Mar 8, 2014 - B, Axial T2 FLAIR image of a 6-year-old girl with acute dissemi- ... children must have frequent lab evaluations. Other common side effects include ..... Clinic in Minnesota: Phone: 800-323-2688 (toll-free) or 507-284-2509.
resected. A posterior annuloplasty is then performed with ... most frequent finding is tricuspid regurgitation secondary ... The DeVega technique is a running.
Wetjen occasionally reviews the medical history,. MRI scans, and videos sent by parents who are considering .... pathologic finding in this class of disorders is the presence of ubiquitin-positive neuronal and glial inclusions in ... officials in Ind
procedure is available at no additional charge to all female patients ... cameras mounted on a modified mammography unit. ... In 1968, Bentall and De Bono de-.
American Association of Clinical Endocrinolo- gists and the Mayo Clinic Division of Endocri- nology, Diabetes, Metabolism, and Nutrition. Hossein Gharib, MD, of the Division of Endo- crinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic in Mi
rence, (2) few local symptoms, (3) intramural origin with eventual ... The gastric tumors were usu- ... Intramural esophageal tumors and duodenal and proxi-.
pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002;50(suppl ...
re-engineering strategies that rely on getting closer to what the consumer is thinking and feeling. Design and innovation firms suggested empathy as a pathway to improved customer services. Renaissance Health even called on Disney Imagineers to help
Feb 22, 2011 - Global tuberculosis control 2010. http:// whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf. ...... AAOS = American Association of Orthopedic Surgeons; ADA = Ameri- can Dental Association; ANP = acute ...... intolerance to a co
mune system launches an attack on the body's own cells or ... prior to starting TNF inhibitor treat- ment. ... abatacept (Orencia); tocilizumab (Actemra); anakinra ...
Dec 22, 2011 - Comorbidities. Neurologic Surgery and Clinical Neurology News ... treatment was often delayed because the cause .... or subdural hygroma.
Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement ..... 3.0T MR-guided laser ablation of a prostate cancer recurrence in the post- surgical prostate ...
5Robotic Thyroidectomy. 6Diabetes and Cancer. Endocrinology News from Mayo Clinic. Vol. 5, No. 3, 2010. EndocrinologyUpdate. In 1984, the adrenal pathologic findings in. 4 Mayo Clinic cases of Cushing syndrome led to characterization of a unique diso
windowed results are shown with dash lines. 111 ...... (2.11). The only parameter that can change the phase of the velocity in the force term is the radiation force function Y which introduces phase Î¸d. The radiation force function for five differen
From the Department of Internal Medicine (A.P.S.), Division of Hospital Inter- nal Medicine (D.J.R.), Department of Family Medicine (S.P.M.), and Division of. General Internal Medicine (F.S.M.), Mayo Clinic, Rochester, MN. This work was supported in
with the ingenuity and heroism of the surgical ... realistic hope that advances in surgical tech- .... the other hand an investigating group who ...... Cancer, N. Y..
Medical informed consent should be an exchange of ideas that buttresses the patient-physician relationship. The consent process should be the foundation of the fiduciary relationship between a patient and a physician. ... their states' statutory laws
Dec 17, 2008 - removing 3- to 10-mm particles) and final filters with a. MERV of 14 .... clean room that is next to an ISO Class 7 positive-pressure anteroom ...
PM&RUpdate Physical Medicine and Rehabilitation News
INSIDE THIS ISSUE
Mayo Clinic Researchers Study Role of Enzyme Drivers of Inflammation and Neurodegeneration in Multiple Sclerosis Treating Recalcitrant Tendinopathy: Combination of Tenotomy and PRP Injections Produces Significant Improvement
Vol. 2, No. 2, 2012
Stem Cell–Based Regeneration: The Next Frontier of Cardiac Tissue Repair Coronary artery disease (CAD) is a major cause of morbidity and mortality. Potent pharmacotherapy, revascularization strategies, cardiac rehabilitation, and aggressive management of cardiovascular risk factors have reduced the recurrence of cardiac events. “A major barrier in the treatment of cardiovascular disease is the inability of the myocardium for self-renewal,” explains Carmen M. Terzic, MD, PhD, chair of Mayo Clinic’s Department of Physical Medicine and Rehabilitation. Testing the hypothesis that replacing injured tissue with healthy tissue could rescue a failing phenotype, Dr Terzic and other Mayo Clinic researchers have focused on developing a stem cell–based strategy to repair diseased cardiac tissue. Stem cell–based regeneration offers the next frontier of medical therapy through delivery of unlimited pools of progenitor cells to achieve structural and functional restoration.
Figure 1. Electron microscopy images of stem cells. Left image: Wild-type control (WT). Right image: Gene knockout, calreticulin gene (crt).
Points to Remember •
Mayo Clinic researchers are seeking to promote myocardial self-renewal with stem cells by gaining a better understanding of the role of nuclear transport during stem cell differentiation and optimizing their properties for cardiac commitment.
Preliminary data indicate significant variation in the cardiogenic potential of stem cells among patients.
Correlating the response to stem cell treatment with presence of specific risk factors for cardiovascular disease may ultimately allow physicians to better predict who can best benefit from stem cell therapy.
Ultimately, augmentation of natural healing or rejuvenation exemplifies on-demand tissue self-renewal without the need for invasive intervention. Internationally, the use of stem cell therapy in patients is currently limited, but preliminary data suggest that this approach may yield modest improvements in cardiac function and structure when treating acute myocardial infarction or chronic heart failure. Dr Terzic has engaged in a variety of research efforts to direct stem cells toward cardiogenesis, to assess the role of nuclear transport during stem cell differentiation and optimize their properties for cardiac commitment. These efforts include developing techniques by which direct injection of stem cells in
Figure 2. A: Normal mouse embryo (WT) with no cardiac abnormalities. B and C: Mice embryos from stem cells with the gene knockout for calreticulin (crt) have cardiac malformation. LV indicates left ventricle; RV, right ventricle. Arrow in lower frame of image C indicates the ventricular septal defect.
Carmen M. Terzic, MD, PhD
a murine model of cardiac infarction engrafts and repopulates the diseased heart with cardiac cells derived from the stem cells (Figures 1 and 2). The ultimate goal is to establish cardiovascular regenerative medicine as a new therapeutic modality for heart disease. Dr Terzic’s team has also gathered preliminary data indicating significant variation in the cardiogenic potential of stem cells among patients. Based on these findings, Mayo Clinic’s Cardiovascular Health Clinic, Department of Physical Medicine and Rehabilitation, and Cardiovascular Research Laboratory are joining forces to introduce stem cell science into the innovative practice of prophylactic medicine to advance personalized wellness. This project involves exploring the individual variation in the number of circulating progenitor cells and their potential to differentiate into cardiac tissue and examining the individual correlation between the cardiogenic potential of circulating progenitor cells and cardiovascular disease risk factors, risk indicators, and clinical outcome. These findings have the potential to help researchers identify novel biomarkers of cardiovascular disease risk, severity, and prognosis; an individual’s self-repair capacity; and the restorative/regenerative effectiveness of secondary prevention therapies. “We are hopeful that a personalized algorithm based on progenitor cell potential would help us identify a high-risk target population with ischemic heart disease that could benefit from cell-based therapy designed to replace progenitor cell deficiencies,” says Dr Terzic. “Because we’ve found that stem cell therapy
MAYO CLINIC | PM&RUpdate
is not beneficial for all patients, we’re examining whether risk factors such as smoking and high glucose may mediate the effectiveness of stem cell therapy for a given individual or a group of individuals with similar risk profiles,” explains Dr Terzic. Correlating the response to stem cell treatment with presence of specific risk factors for cardiovascular disease may ultimately allow physicians to better predict who can best benefit from stem cell therapy. Inducible progenitor cells are another type of recently described stem cells that have been used by Dr Terzic. What makes these cells “incredible” is the fact that inducible progenitor stem cells are obtained by expressing a set of 4 genes into a mature cell, such as a fibroblast. The fibroblasts expressing these genes “regress” to a state of undifferentiated stem cells that are similar to the embryonic stem cells. “This approach is of importance because it could allow us to obtain pluripotent embryonic cells without using embryos, eliminating ethical issues,” says Dr Terzic. “It also prevents the rejection of these cells as we can obtain the pluripotent cells from fibroblasts derived from the skin of the same individual who is in need of the stem cells.” Translating cardiac cell repair therapy into clinical practice is an intriguing and challenging objective. Dr Terzic and her colleagues are hopeful that this new knowledge will eventually guide clinicians in choosing the most effective reparative phenotype for each patient and help them optimize the delivery, dosing, and timing of these new forms of intervention. This fascinating field is making rapid progress that certainly merits close attention.
Mayo Clinic Researchers Study Role of Enzyme Drivers of Inflammation and Neurodegeneration in Multiple Sclerosis Multiple sclerosis (MS) is the leading cause of nontraumatic neurologic disability in young adults in North America, yet there are no uniformly effective therapies and none yet proven effective at blocking long-term progression. The difficulty in predicting disease course and in developing effective treatments is complicated by the heterogeneity of the disease, which can manifest with a benign, relapsing/remitting, or progressive disease course. Since effective therapeutic options are very limited for MS patients, particularly when the disease is in its more progressive stages, it becomes essential to define both pathophysiologic mediators of each stage and markers that would permit individualized therapeutic intervention. The clinical manifestations of MS, whether relapsing or progressive, are believed to relate in part to the degree of inflammation relative to neurodegeneration, which characterizes the individual disease course. Advances in genetics, protein chemistry, and bioinformatics and, most importantly, a skilled community of research and clinical experts create a fertile environment for Mayo Clinic’s MS research team. Recently, Mayo researchers have discovered that select members of a family of secreted serine proteases known as tissue kallikreins play key roles in both the inflammatory and neurodegenerative processes that drive MS and may serve as important biomarkers of
Figure 1. Whole sections of mouse spinal cord were grown in an organotypic slice culture system to study the interactions between nerve impulse–conducting axons (stained for neurofilament protein [green]) and glial cells referred to as astrocytes (stained for glial fibrillary acidic protein [red]). Cells were visualized using confocal fluorescence microscopy. Cell nuclei were stained blue with 4’,6-diamidino-2-phenylindole. (Picture by Hye-Sook Yoon, PhD, Research Fellow, Mayo Clinic Physical Medicine and Rehabilitation Research)
Points to Remember •
Select tissue kallikreins play key roles in the inflammatory and neurodegenerative processes driving multiple sclerosis (MS).
Kallikrein 1 and kallikrein 6 are elevated in the blood and brain lesions of MS patients and appear to contribute to pathology.
Kallikrein 1 and 6 each correlate with disability scores.
These enzymes may be important therapeutic targets in treating both the neurodegenerative and inflammatory lesions in progressive MS.
Isobel A. Scarisbrick, PhD
disease stage and future disability. Tissue kallikreins comprise a family of 15 mainly newly identified serine proteases. These proteases comprise the largest continuous cluster of serine proteases in the human genome, although they have as yet poorly defined roles in disease. Mayo Clinic’s MS researchers are focusing on two members of the kallikrein protease family that are elevated in the blood and brain lesions of MS patients and which show strong evidence of contributing to pathology. In a study published in 2008, Mayo researchers showed that kallikrein 1 and kallikrein 6 are selectively elevated in the serum of MS patients experiencing a progressive disease course (when compared with patients with relapsing/remitting disease or to non-MS controls). Importantly, in cell culture studies each of these was shown to exert neurotoxic effects toward central nervous system (CNS) neurons. Kallikrein 6 was also particularly toxic to the myelin-producing oligodendrocytes. Interestingly, kallikrein 1 levels were found to correlate with Expanded Disability Status Scale (EDSS) scores at the time of serum draw, while kallikrein 6 serum levels were predictive of future EDSS worsening. Additional research published in 2011 has shown that each kallikrein drives unique aspects of the inflammatory processes that underpin MS pathogenesis, with kallikrein 1 promoting lymphocyte proliferation while kallikrein 6 increased the resistance of lymphocytes to apoptosis. These findings predict a clinical model in which
MAYO CLINIC | PM&RUpdate
elevated levels of kallikrein 1 and kallikrein 6 at sites of CNS inflammation likely contribute directly to sustained chronic inflammation and neurodegeneration. These enzymes thus become important therapeutic targets in treating both the neurodegenerative and inflammatory events that so often characterize lesions in patients experiencing a progressive disease course. A major advance in understanding 1) the mechanism of action of kallikreins in MS and other neurologic disorders and 2) how these enzymes might be targeted therapeutically came with the discovery that kallikreins can activate protease-activated receptors to trigger discrete intracellular signaling cascades involved in inflammation and CNS injury. Current research is therefore focused on determining the effects of genetic and pharmacologic modulation of these receptors in the CNS or in the immune compartments in animal models of MS. Mayo researchers are hopeful that the insights provided will point directly to new therapies for MS patients, particularly those at the more progressive stages of disease. In a study published this year in Brain Pathology, Mayo researchers found that an antibody that neutralizes kallikrein 6 is capable of staving off MS in mice. “We were able to slow the course of disease through early chronic stages, both in the brain and spinal cord,” says lead author Isobel A. Scarisbrick, PhD, of Mayo Clinic’s Department of Physical Medicine and Rehabilitation. Dr Scarisbrick and colleagues studied mice infected with Theiler’s murine encephalomyelitis virus (TMEV), a viral model of MS, and assessed the effects of kallikrein 6–neutralizing antibodies on disease progression. RNA expression of kallikrein 6 was elevated in the brain and spinal cord by 7 days postinfection (dpi), and expression persisted primarily in the spinal cord, reaching a peak of five-fold over controls at mid-chronic stages (60 dpi–120 dpi). Significant elevations in kallikrein 6 RNA were also induced in lymphocytes stimulated with viral capsid proteins in vitro and in activated human acute monocytic leukemia cells. September 2011 Regional News ●
Mayo Clinic in Arizona Mayo Clinic in Florida Mayo Clinic in Minnesota Clinical Trials
Clinical Trials Open to
Recruitment Referring a Patient Arizona Referrals
See Medical Professiona
page for more physician
Comments? We're interested in your feedback. Pass It On Invite a colleague to subscribe by forwarding this newsletter.
MAYO CLINIC | PM&RUpdate
Patient Care Mayo Clinic Launches Hand Transplant Program
Mayo Clinic is on the leading edge of a new era in transplantat ion aimed at improving the quality of life for people who have sustained debilitating injuries. Mayo’s new hand transplant dramatic difference in or amputation of both
program in Rochester,
the day-to-day lives of hands.
Minnesota, can make a people with severe hand injuries
PM&R Welcome to the first issue of Physician Update e-mail newsletter. This newsletter will offer access to articles from the PM&R print publication, plus other items of general audience.
Over the past 2 decades, researchers have explored the possibility of developing an implantable diaphragma tic pacing device to improve the quality of life for
Kallikrein 6–neutralizing antibodies reduced TMEV-driven brain and spinal cord pathology and delayed-type hypersensitivity responses when examined at early chronic time points (40 dpi). The effects of kallikrein 6 on spinal cord pathology included a decrease in activated monocytes/microglia (inflammatory white blood cells) and a reduction in the loss of myelin basic protein, a key component of the myelin sheath. By 180 dpi, pathology scores no longer differed between groups. The kallikrein 6–neutralizing antibody had reduced inflammation and demyelination through early chronic time points, and the investigative team hopes to develop more powerful enzyme-inhibiting techniques to determine if more long-term effects can be achieved. “These findings suggest kallikrein 6 plays a role in the inflammatory and demyelinating processes that can accompany many types of neurologic conditions,” says Dr Scarisbrick. “In the early chronic stages of some neurologic diseases, therefore, kallikrein 6 may represent an excellent drug target to coordinately reduce inflammation and myelin loss. ”
interest to a physician
Mayo Clinic Offers Implantable Diaphrag matic Pacing System for Spinal Cord Injury Patients
Figure 2. Fluorescence photomicrograph shows dissociated cultures of myelin producing oligodendroglia (stained for sulfatide [green]) and astrocytes (stained for glial fibrillary acidic protein [red]). The culture system allows determination of factors such as kallikrein 6 which affect myelination. (Picture by Maja Radulovic, PhD candidate, Mayo Clinic Neurobiology of Disease Program)
Inpatient Rehabilit ation Unit Renovati on Nears Completi Located at Saint Marys on Hospital in Rochester, Minnesota, the inpatient unit has continually rehabilitation
updated its services and infrastructure to provide the best care to every patient every day. The unit serves Mayo Clinic patients of all ages comprehensive spectrum with a of accredited rehabilitatio n programs.
Mayo Clinic Research ers Test the Feasibilit y and Efficacy of Telehealt h-Based Cognitive Rehabilitation for Individuals With TBI Traumatic brain injury (TBI) is a serious public
health concern associated extensive residual impairments with , including cognitive difficulties, such as memory and executive dysfunction, which can result in lifelong disability.
Research Therapeutic Exercise During Outpatient Radiation Therapy for Advanced Cancer: Feasibility and Impact on Well-being
Interested in receiving Mayo Clinic physical medicine and rehabilitation news in your inbox? Go to www.mayoclinic.org/publications/medicalprofs-enews.html to sign up for Mayo Clinic’s Physician Update–PM&R e-mail newsletter.
Treating Recalcitrant Tendinopathy: Combination of Tenotomy and PRP Injections Produces Significant Improvement Recently recognized as primarily a degenerative condition, tendinopathy (previously called tendinitis) is characterized by hypercellularity, vascular hyperplasia, and collagen disorganization. Nonoperative treatment of tendinopathy includes correction of biomechanical factors, kinetic chain deficits, and training errors; activity modifications, stretching, strengthening, endurance, and proprioceptive exercises; and bracing, physical modalities, and medications. When nonoperative interventions fail to relieve symptoms, additional treatment options that attempt to stimulate tissue regeneration can be considered. Emerging therapies include tendon fenestration (percutaneous tenotomy), and platelet-rich plasma (PRP) injections. During tendon fenestration, the practitioner uses ultrasound to make multiple needle passes through the injured area to stimulate tissue healing. This process disrupts tendinopathic tissue and induces bleeding. The bleeding leads to clot formation and release of growth factors. “The goal of this treatment is to convert a chronic, nonhealing injury into an acute injury with increased healing potential, “ explains Physical Medicine and Rehabilitation physician Jay Smith, MD, who specializes in sports medicine and musculoskeletal ultrasound at Mayo Clinic in Rochester. Another promising new treatment for refractory tendinopathy is PRP injection. Used for more than a decade to facilitate the healing of difficult wounds, PRP is rich in growth factors linked to healing. Using ultrasound guidance, practitioners inject the PRP into the affected tendon, usually following a tendon fenestration procedure. It is theorized that when PRP is injected into an area of tendinopathy, the platelets release growth factors and stimulate a healing response. “The fenestration breaks up the abnormal tissue, and then we inject the platelets into the prepared area to promote healing,” explains Dr Smith. PRP is created from an autologous wholeblood sample through a platelet separation process, which results in an increased platelet concentration compared with the original whole blood sample. In a recent study published in the journal PM&R, Mayo Clinic researchers reported that
Points to Remember •
During tendon fenestration (percutaneous tenotomy), the practitioner uses ultrasound to make multiple needle passes through the injured area to stimulate tissue healing.
Used for more than a decade to facilitate the healing of difficult wounds, platelet-rich plasma (PRP) injections are another promising new treatment for refractory tendinopathy.
Jay Smith, MD
Mayo Clinic researchers found that more than 70 percent of patients treated with a combination of tenotomy and PRP injections had better use of their tendons, and 76 percent reported improvement in pain.
the combination of tenotomy and PRP injections produced significant improvement in many patients with long-standing tendon injuries. The study included 34 patients with a wide range of tendon and soft tissue injuries, from tennis elbow (lateral epicondylitis) to plantar fasciitis, an inflammation on the bottom of the foot. “These disorders can be hard to treat, and patients tend to receive one therapy or the other (tenotomy vs PRP), depending on what a doctor happens to offer. Our study was the first clinical study to investigate the combination of both treatments in injured tendons,” says Dr Smith. Researchers found maximum benefits tended to occur within four months after the procedure. More than 70 percent of patients had better use of their tendons, and 76 percent reported improvement in pain. In addition, researchers found some indication of tendon healing, which was detected with sophisticated ultrasound imaging. “Larger studies are still necessary to determine whether the combination is particularly helpful for certain injuries or types of tendons, but this investigation showed these therapies together are safe and effective for some people who have an ongoing tendinopathy,” says Dr Smith.
MAYO CLINIC | PM&RUpdate
Mayo Clinic PM&R Update Medical Editors: Carmen M. Terzic, MD, PhD Mary L. Jurisson, MD
Mayo Clinic PM &R Update is written for physicians and should be relied upon for medical education purposes only. It does not provide a complete overview of the topics covered and should not replace the independent judgment of a physician about the appropriateness or risks of a procedure for a given patient.
Contact Us Mayo Clinic welcomes inquiries and referrals, and a request to a specific physician is not required to refer a patient.
Education Opportunities Mayo Clinic Symposium on Concussion in Sport September 28-29, 2012 Scottsdale, Arizona Offered both onsite and as a webcast, this state-of-the-art symposium highlights the epidemiology of concussion in sport; the pathophysiology of concussion; sideline and outpatient clinical evaluation; standard and novel diagnostic strategies; and implementation of return-to-activity guidelines. The format includes platform lectures, small group workshops, panel discussions, and live two-way remote audio/video concussion evaluations using robotic teleconcussion technology. Contact: 480-301-4580 or e-mail: [email protected]
The Neurorehabilitation Summit October 25-26, 2012 Rochester, Minnesota This summit provides practitioners with updates that address three common areas of neurologic care: brain disorders, spinal cord dysfunction, and neurodegenerative diseases. Renowned speakers will discuss advancements in clinical practice, research, and innovation throughout the continuum of care. Contact: 800-323-2688 or e-mail: [email protected]
22nd Annual Mayo Clinic Symposium on Sports Medicine November 9-10, 2012 Rochester, Minnesota This case-oriented program provides an integrated approach to the injured athlete and includes case presentations, lectures, and video demonstrations. Health care professionals with an interest in sports medicine and athletic trainers will find this program appropriate. Contact: 800-323-2688 or e-mail: [email protected]
Update in EEG, EMG, and Clinical Neurophysiology February 24 - March 2, 2013 Amelia Island, Florida This course will review clinical neurophysiology techniques and topics, including basic physiology, pathophysiology, EEG, evoked potentials, EMG, movement disorders, and intraoperative monitoring. Focus will be on neurophysiologic tests for epilepsy, sleep disorders, movement disorders, peripheral nerve, and neuromuscular disorders. Contact: 800-323-2688 or e-mail: [email protected] See all Continuous Professional Development courses at http://www.mayo.edu/cme
mayoclinic.org/medicalprofs Clinical trials, CME, Grand Rounds, scientific videos, and online referrals